Jenna Payesko

These findings are among the first in the United States to indicate an association between migraine and atrial fibrillation.

The positive topline results from Study 201 have led to the initiation of an open-label extension for the subjects previously enrolled in Study 201, which is set to begin later this year.

The BAN2401 International Project Team Leader and Clinical Lead spoke about how the introduction of a novel, potentially disease modifying therapy would represent a paradigm shift in the field.

Eli Lilly intends to submit a supplemental biologics license application to the FDA for galcanezumab for the preventive treatment of episodic cluster headache by the end of 2018.

If approved, lasmiditan could represent the first significant innovation for acute treatment of migraine in more than 2 decades.

The Carolyn and Matthew Bucksbaum Professor of Clinical Ethics at the University of Chicago spoke about the ethical considerations of spinal muscular atrophy and its treatment.

The Founder and CEO of NeuroTrials Research spoke about the current landscape of insomnia, noting that lemborexant holds promise as a potential therapy.

Tracking mandibular movements is a useful tool when measuring the efficacy of oral appliance therapy in obstructive sleep apnea.

Researchers found a link between atrial fibrillation and an increased risk of dementia and concluded that anticoagulants could help decrease that risk.

The clinical professor in pediatric neurology and director of regional neurology services at Children's Hospital Colorado shared her thoughts on why epilepsy is the perfect paradigm to implement telemedicine.

In clinical trials, differences in the use of cholinesterase inhibitors and memantine between treatment and placebo groups may lead to the conclusion that a treatment is effective when it is not, or vice versa.

The Pediatric Movement Disorders Neurologist at UT Southwestern recommends that when encountering a patient with a movement disorder to organize your thought process in 3 steps.

Trial results showed a reduction of 61% in disease progression in both primary efficacy endpoints measuring cognition and activities of daily living at 14 months.

Darryl De Vivo, MD, emphasized that while there's been a tremendous advance in the field of SMA, it’s important to continue tinkering around the margins to make the effective treatment increasingly better.

Sodium oxybate is the first therapy approved to treat cataplexy or excessive daytime sleepiness in pediatrics with narcolepsy 7 years of age and older.

The Sidney Carter Professor of Neurology at Columbia University Medical Center spoke about the 127 year history of spinal muscular atrophy and how basic science has led to exciting developments.

The approval and immediate launch of the product in both tablet and oral suspension offer a generic alternative to Onfi.

The Associate Clinical Professor at the University of South Carolina School of Medicine and Chief Medical Officer at SleepMed emphasized that clinicians need to recognize the impact of sleepiness in terms of quality of life.

Neuropsychiatric symptoms are now recognized as hallmarks of dementia and are important targets for the development of effective treatments.

Both doses of lemborexant reduced subjective sleep onset latency for patients with insomnia.

The guidance provides clinicians with tools allowing for earlier and more accurate diagnosis of Alzheimer disease.

If approved, siponimod would be the first oral disease-modifying therapy with the potential to delay secondary progressive multiple sclerosis progression.

The medical director of digital health at Cleveland Clinic spoke about the role telehealth plays in a society where technology constantly advances and changes.

The pediatric neurologist discussed the importance of the recent FDA approval of perampanel in pediatrics with partial-onset seizures with or without secondarily generalized seizures.

The restless leg syndrome expert spoke about the commonality of both pediatric and adult patients oftentimes misdiagnosed or undiagnosed with RLS.

Digital medicine is used to increase access for rural and underserved areas, allowing for the delivery of patient care, patient monitoring and specialist consultations.

Safety data for pediatrics was consistent with the safety profile in adult populations, without the need for weight-based dosing.

The Director of Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the importance of clarity in patient identification and assessment.

The Director of Cleveland Clinic Lou Ruvo Center for Brain Health spoke about the rapidly changing landscape of treatments for Alzheimer disease.

The Johns Hopkins Associate Professor spoke about the current therapeutic landscape of restless leg syndrome, an often misdiagnosed disorder.